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Abstract
Background: Mycoplasma genitalium (MG) causes urethritis, cervicitis and pelvic inflammatory disease. The MG treatment
failure rate using 1 g azithromycin at an Australian Sexual Health clinic in 2007–9 was 31% (95%CI 23–40%). We developed a
rapid high resolution melt analysis (HRMA) assay targeting resistance mutations in the MG 23S rRNA gene, and validated it
against DNA sequencing by examining pre- and post-treatment archived samples from MG-infected patients.
Methodology/Principal Findings: Available MG-positive pre-treatment (n=82) and post-treatment samples from
individuals with clinical treatment failure (n=20) were screened for 23S rRNA gene mutations. Sixteen (20%) pre-treatment
samples possessed resistance mutations (A2058G, A2059G, A2059C), which were significantly more common in patients
with symptomatic azithromycin-treatment failure (12/26; 44%) than in those clinically cured (4/56; 7%), p,0.001. All 20
patients experiencing azithromycin-failure had detectable mutations in their post-treatment samples. In 9 of these cases,
the same mutational types were present in both pre- and post-treatment samples indicating transmitted resistance, whilst
in 11 of these cases (55%), mutations were absent in pre-treatment samples indicating likely selection of resistant isolates
have occurred. HRMA was able to detect all mutational changes determined in this study by DNA sequencing. An additional
HRMA assay incorporating an unlabelled probe was also developed to detect type 4 single-nucleotide polymorphisms
found in other populations, with a slightly lower sensitivity of 90%.
Conclusions/Significance: Treatment failure is associated with the detection of macrolide resistance mutations, which
appear to be almost equally due to selection of resistant isolates following exposure to 1 g azithromycin and pre-existing
transmitted resistance. The application of a rapid molecular assay to detect resistance at the time of initial detection of
infection allows clinicians to shorten the time to initiate effective second line treatment. This has the potential to reduce
transmission of resistant strains and to avoid sequelae associated with persistent untreated infection.
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Introduction
Mycoplasma genitalium was first isolated in 1980 from men with
non-gonococcal urethritis (NGU) [1] [2] and has since been
established as a sexually transmitted infection [3] responsible for
20–35% of non-chlamydial NGU, as well as cervicitis. Evidence is
mounting to suggest that MG plays a role in other conditions such
as endometritis, pelvic inflammatory disease and tubal factor
infertility in women [4,5,6,7,8] plus balanoposthitis in men [9]. As
MG is a fastidious organism, making a diagnosis with conventional
culture technique is difficult and requires the use of sensitive
nucleic acid amplification tests (NAATs). Commercially available
kits are becoming available for the detection of MG, such as the
AmpliSensH Mycoplasma genitalium-EPh PCR kit, Bio-Rad Dx CT/
NG/MG assay, EuroClone DUPLICa kit, and Gen-Probe;
however none as yet have obtained US FDA approval. Hence
current testing is predominately based on clinical services with
validated in-house PCR assays [10]. To accurately determine
whether an MG infection has been successfully treated, a test of
cure (TOC) using PCR-based assays is generally deferred for at
least 2–4 weeks, to avoid the detection of non-viable DNA that can
persist post-treatment resulting in false positive results [11]. This
limitation results in significant delays in establishing whether an
infection has been adequately eradicated, with the potential for
ongoing transmission and persistent symptoms for infected
individuals.
The current recommended treatment for MG infection is the
macrolide antibiotic azithromycin [12]. One comparative trial and
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azithromycin is significantly more effective than the multi-dose
doxycycline, with cure rates of 86–87% compared with 22–45%
respectively [11,13]. In addition an extended azithromycin
regimen (500 mg on day 1 followed by 250 mg daily for 4 days)
cured .95% of doxycycline treatment failure cases. The extended
regimen of azithromycin has been evaluated in a number of
observational studies with cure rates reported to range from 74–
96% [11,14].
Routine testing for MG commenced at the Melbourne Sexual
Health Centre (MSHC), Australia, in 2005 for symptomatic
individuals presenting with urethritis, cervicitis, pelvic inflamma-
tory disease or of sexual contacts of MG-infected individuals. Two
clinical audits (March 2005 to November 2007 and December
2007 to August 2009) were conducted following the onset of
testing to determine the effectiveness of 1 g azithromycin for
treating MG infection. The efficacy of azithromycin was found to
be 84% in the first audit period [15], and declined to 69% in the
second audit period (p,0.001) [16]. Previous work had identified
a number of macrolide resistance mutations (A2058G, A2059G) in
a small subset of individuals experiencing treatment failure with
azithromycin at MSHC in 2004. However, the proportion of cases
with treatment failure attributable to azithromycin resistance
mutations in the clinical population and how many were likely due
to transmitted (pre-existing) resistance compared to those selected
for (following azithromcyin) was not known [17].
The mode of action of macrolide antibiotics such as
azithromycin is preventing bacterial multiplication by binding to
the 50S subunit of the ribosome (which includes the 5S and 23S
subunits) and inhibiting translation of mRNA; hence interfering
with protein synthesis. Resistance to macrolide antibiotics can
occur through mutational changes that in turn inhibit binding of
the macrolide. Such mutational changes, in particular those
occurring in nucleotide positions 2058 and 2059 in region V of the
23S rRNA gene (E. coli numbering), have been well characterized
in those of the bacterial class Mollicutes such as M. pneumoniae,a
close relative of MG [18]. The macrolide resistance seen in M.
pneumoniae infections is increasing at an alarming rate particularly
in Asia, among patients with community-acquired pneumonia and
respiratory tract infections, primarily as the result of an increase in
circulation of these resistant strains in the community [19,20].
This resistance pattern has since been documented with MG
infections, being predominantly adenine to guanine transitions in
either 23S rRNA gene position 2058 or 2059 [17,21,22,23].
Rapid assays have been developed for the detection of
macrolide resistance in M. pneumoniae based on High Resolution
Melt Analysis (HRMA) [24,25]. HRMA is performed when
double-stranded DNA is exposed to increasing temperature
gradient for gradual denaturing from double-stranded to single-
stranded DNA, at a rate based on its nucleic acid content.
Different nucleic acid compositions will therefore denature at a
different rate and HRMA is ideally able to discriminate a single
base change in the target DNA. The incorporation of a sensitive
fluorescent dye that intercalates only with double-stranded DNA
allows for the real-time monitoring of the melt profiles, giving a
measureable profile that can be compared to standards. HRMA is
a relatively inexpensive and rapid molecular method for the
detection of single nucleotide changes.
This study describes the application of HRMA for the rapid
detection of key mutations in stored clinical samples from MG
infected males and females who attended MSHC during 2007–9.
The aim was to determine the prevalence of macrolide resistance
mediating mutations (MRMM) in the study population, whether
MRMM were contributing significantly to clinical treatment
failure, as well and determine the proportion of mutations that
were transmitted (present in pre-treatment samples) or selected
(present in post-treatment samples only). Azithromycin failure is
becoming an increasing clinical problem in the treatment of MG
infections, and the application of a rapid molecular assay to
identify resistance could facilitate the timely choice of second line
agents, which has the potential to reduce transmission of resistant
strains and avoid sequelae associated with persistent untreated
infection.
Materials and Methods
Study samples and controls
Samples were derived from an audit conducted between 11/
2007 and 8/2009 at MSHC whereby 111 MG-infected individuals
were treated with 1 g of azithromycin and returned for clinical
follow-up at one month together with a test of cure (TOC); 86
males and 25 females [16]. Of the 111 patients, stored pre-
treatment samples were available from 82 (74%): 20 from women
and 62 from men. Of the 26 participants experiencing clinical
treatment failure following 1 g of azithromycin in this period, 20
(77%) post-treatment samples were available. Treatment failure
was defined microbiologically as a persistently positive PCR
approximately 4 weeks after 1 g of azithromycin. A detailed sexual
history to indicate risk of reinfection was obtained from
participants experiencing treatment failure, but not from those
experiencing cure. Positive TOC cases were treated with 400 mg
moxifloxacin daily for 10 days, where reinfection was considered
unlikely. All samples were either stored at 230uC or stored at
room temperature using the DNAstable DNA storage system
(Biomatrica, San Diego USA). For the validation of each HRM
assay, purified DNA from 18 previously characterized macrolide
resistance isolates was used and subsequently used as controls for
each 23S rRNA gene mutation type, with M. genitalium G37
genomic DNA (ATCC 33530D) serving as the wild type control
(Table 1). In addition, 50 consecutive MG negative samples (40
males/10 females) were included to test for nonspecific amplifi-
cation. Ethics approval, where necessary, was gained from the
Alfred Hospital (Melbourne, Australia).
23S rRNA gene sequencing
PCR targeting a 147 bp region of the M. genitalium 23S rRNA
gene was carried out using the primers Mg23S1992F (59-CCA
TCT CTT GAC TGT CTC GGC TAT-39) and Mg23S2138R
(59-CCT ACC TAT TCT CTA CAT GGT GGT GTT-39) [17].
The PCR consisted of 10 ml of template DNA, 16Green GoTaqH
Flexi Buffer, 2 mM MgCl2 (Promega), 0.2 mM of each dNTP
(Invitrogen), 1.25 units of GoTaqH DNA polymerase, and 0.5 mM
of each primer PCR in a 50 ml reaction volume. Amplification was
performed using a GeneAmpH PCR System 9700 (Applied
Biosystems) with the following parameters: activation of the
enzyme at 95uC for 10 min, followed by 50 cycles consisting of
95uC for 15 seconds and 60uC for a minute. PCR products were
visualized on a 2% agarose gel stained with GelRed (Biotium,
Hayward CA USA). PCR amplicons were purified using the
Agencourt AMPure XP System (Beckman Coulter, Pasadena CA
USA) and quantified using the QubitH dsDNA HS Assay Kit
(Invitrogen, Carlsbad CA USA). DNA sequencing was carried out
at the Australian Genome Research Facility using an AB 3730xl
capillary sequencer (Applied Biosystems, Foster City CA USA).
Sequence analysis was carried out using DNAStar (Lasergene) and
SeaView [26]. Accession numbers for each 23S rRNA gene
sequence type are shown in Table 1.
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Two assays were developed for the discrimination of M.
genitalium 23S rRNA gene resistance types, by HRMA. Each assay
was run on a LightCycler 480 real-time instrument (Roche
Diagnostics, Indianapolis USA) with 5 ml template DNA in a 20 ml
reaction. The enzyme mix used in this study was the MeltDoc
HRM Mix (Applied Biosystems, Foster City USA). Each reaction
consisted of an initial PCR amplification step with the same
cycling conditions as for the 23S rRNA gene PCR, followed by a
95uC step for one minute, 40uC for one minute, and a melt cycle
from 65–95uC at a ramp rate of 0.02uC per second and 25
fluorescent acquisitions per second. The first assay adopted the
Mg23S1992F and Mg23S2138R primers used for the 23S rRNA
gene sequencing, with the addition of an unlabelled probe
phosphorylated at the 3 prime end, Mg23S2053Pb (59-GAC
GGA AAG ACC CCG TGA AG Phos-39), at concentrations of
40 nM, 200 nM and 200 nM per reaction respectively. The probe
implemented in this study shares a 100% homology to the M.
genitalium 23S rRNA gene wild type sequence. The second assay
targeted a 67 bp region of the 23S rRNA gene using the forward
primer Mg23S1998F (59-AAT CCA GGT ACG GGT GAA GA-
39) and the reverse primer Mg23S2080R (59-CAG TAA AGC
TTC ACG GGG TCT-39) at a concentration of 200 nM per
reaction. Oligonucleotide sequences not previously published were
designed using Primer3 [27] and the BLAST search engine at the
National Center for Biotechnology Information (http://www.ncbi.
nlm.nih.gov/BLAST).
Statistical methods
Data were analysed using PASW software (version 18).
Differences between categorical variables were compared using
the Chi-square or Fisher’s Exact test where appropriate, and
proportions were compared using a t-test. Sensitivity and
specificity calculations were carried out using DAG_Stat [28].
Results
Description of the study population
Of the 111 MG-infected patients treated with 1 g azithromycin
who attended for TOC, 77 (69%; 95%CI=60–77%) were cured
with 1 g azithromycin and 34 (31%; 95%CI=23–40%) were not.
Treatment failure was not significantly associated with any
demographic or behavioral characteristics including gender or
sexual partner from outside Australia (p.0.10). Of these 111
cases, 82 (74%) stored pre-treatment samples (62 male; 20 female)
and 20 (77%) post-treatment MG positive samples were able to be
sourced and were of sufficient quality to be utilized in this study.
There were no significant differences in demographic or
behavioral characteristics between the 82 individuals included in
the analysis of stored samples and the 29 excluded (Table 2).
Importantly, the treatment failure rate in the individuals in whom
stored samples were available did not differ from those excluded
(28%, 95%=14–46%), or the overall study population (31%,
95%=23–40%) (Table 3). The test of cure for MG in the 20 cases
included in this study was undertaken at a median of 30 days
(range=14–127 days; IQR=24.25 days) after treatment. Sexual
history was available in 14 of 20 cases of treatment failure: 6 had a
probable/definite risk of reinfection, 8 had no risk of reinfection as
they were celibate and 6 had an unknown risk with insufficient
sexual history available. A risk of reinfection was defined as one
being sexually active with a partner between treatment and test of
cure. All cases of persistent MG infection following azithromycin
were ultimately cured with moxifloxacin 400 mg daily for 10 days.
Macrolide resistance in pre-treatment M. genitalium
positive samples
Overall, 23S rRNA gene sequences spanning positions 2058
and 2059 (E. coli numbering) were obtained for the 82 pre-
treatment MG samples in this study; 16 (19.5%) possessed 23S
rRNA mutations (A2058G, A2059G, A2059C) indicating trans-
mitted or circulating macrolide resistance (Information S1). Of the
26 individuals with treatment failure at TOC, 12 (46%) were
found to have pre-existing resistance, whereas only 4 (7%) of the
56 individuals with a negative TOC had pre-existing resistance
(p,0.0001) (Table 4). Thus, pre-existing resistance was strongly
associated with treatment failure following 1 g of azithromycin.
Macrolide resistance in test of cure M. genitalium positive
samples
The 20 post-treatment samples from individuals with treatment
failure after 1 g azithromycin were tested for macrolide resistance
mutations. All 20 cases were shown to possess 23S rRNA gene
mutations in post-treatment samples (Table 5), consisting of
A2059G (60%), A2058G (35%) and A2059C (5%). In 9 (45%) of
these cases, mutational changes of the same type were detected in
both the pre and post-treatment samples indicating transmitted
resistance. Sexual histories on the 5 of 9 cases were available and
all but one had been celibate in between treatment and test of cure
whilst one had a possible risk of reinfection having been sexually
active. Possession of a pre-existing macrolide resistant MG
infection was not associated with having an overseas sexual
partner. Eleven (55%) cases had a wild type 23S rRNA gene
sequence on their pre-treatment sample, but had macrolide
mutations detected on post-treatment samples; sexual history was
available on 9 of the 11 patients with 4 being celibate in between
treatment and TOC, 4 having a possible risk of reinfection having
Table 1. 23S rRNA gene mutations associated with macrolide
resistance in M. genitalium.
Mutation (E. coli numbering) Strain Reference
A2059G W68551
a -
W1327
a -
W2332
a -
H65213
a -
T63708
a -
M6270 [33]
A2058C M6302 [17]
A2058G F61048
a -
F61355
a -
H64377
a -
M16670
a -
W4806
a -
W4564
a -
M6321 [17,29]
A2058T F3200
a -
M50367
a -
M14770
a -
A2059C F32379
a -
Wild Type G37 ATCC 33530D
a– Characterized at Statens Serum Institut (Copenhagen, Denmark).
doi:10.1371/journal.pone.0035593.t001
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untreated sexual partner. There was no significant difference
observed between the mutation types and whether the patient
possessed a pre-existing or selected resistant MG strain. One
sample analyzed from a male who originally carried a wild type
sequence, possessed both wild type and A2058G sequence types in
his positive test of cure sample. It is likely that this patient was
tested during the transition phase, as his TOC was carried out 17
days post treatment and there was no risk of re-infection as he was
consistently celibate over the period of follow up and TOC.
Macrolide resistance in persistent M. genitalium positive
case
One of the aforementioned azithromycin treatment failure cases
was a male with a positive TOC 37 days after treatment that was
confirmed by repeat MG testing. The patient was re-treated with
1 g azithromycin and returned for a second TOC 42 days later
that remained positive. This individual had not been sexually-
active since initial diagnosis and treatment. At the second positive
TOC he was given moxifloxacin 400 mg daily for 10 days and
successfully cleared his persistent MG infection. DNA sequencing
revealed this patient initially carried a wild type MG infection and
that at the first and second TOC only a A2058G resistant type was
detected. As this patient demonstrated no reinfection risk it
appears that exposure to 1 g azithromycin is likely to have selected
for resistance.
HRMA limit of detection
A HRMA assay using a 147 bp amplicon flanking the 23S
rRNA gene mutation sites was initially adopted, although an
incorporation of an unlabelled probe was necessary to detect the
A2058T sequence type. This assay was able to amplify purified M.
genitalium culture DNA sufficiently to determine this resistance type
down to 10–100 copies per reaction, and was able to differentiate
Table 2. Characteristics of patients treated with 1 g azithromycin for MG and presented for a test of cure at Melbourne Sexual
Health Centre between December 2007 and December 2009.
Whole study population (n=111)
Participants in study
(n=82) Non-participants (n=29)P value
a
Mean age +/2SD 31.3+/28.4 31.3+/29.0 31.4+/26.6
Male (%) 86 (78) 62 (76) 24 (83) 0.43
Female (%) 25 (22) 20 (24) 5 (17)
Mean number of male partners previous 3
months
b
1.4+/22.7 1.4+/22.6 1.4+/23.0
Overseas partner
No (%) 77 (70) 57 (70) 20 (69)
Yes (%) 34 (30) 26 (30) 9 (31) 0.62
IDU
No (%) 107 (97) 79 (98) 28 (98)
Yes (%) 3 (3) 2 (3) 1 (3) 0.78
Symptomatic
No (%) 11 (10) 9 (11) 2 (7)
Yes (%) 100 (90) 73 (89) 27 (93) 0.53
a– p value calculated comparing participants to those excluded.
b– period before initial test was positive.
doi:10.1371/journal.pone.0035593.t002
Table 3. Summary of 2007–2009 MG positive samples available for 23S rRNA gene mutation screening.
N
Total number of MG positive cases (2007–9) 111
Successfully treated with 1 g azithromycin 77 (69%)
Test of cure positive after 1 g azithromycin 34 (31%)
Median time for test of cure testing 35 d (range=14–127 d)
Total number cases available for 23S rRNA SNP screening 82/111 (74%)
Successfully treated with 1 g azithromycin 56 (68%)
a
Test of cure positive after 1 g azithromycin 26 (32%)
b
Median time for test of cure testing 30 d (range=14–127 d)
a– 39 male, 17 female.
b– 23 male, 3 female. Of these 26 cases, 20 (18 male, 2 female) corresponding test of cure samples samples were available for analyses. One of these was a persistent
case comprising 3 MG positive test of cure samples at 37, 5 and 37 days between positive results.
doi:10.1371/journal.pone.0035593.t003
Detection of Macrolide Resistance in M. genitalium
PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e35593the wild type from each mutant types tested (Figure 1), with an
average Tm of 85.12uC (SD=0.27uC). Using a smaller amplicon
size of 67 bp (with no unlabelled probe), the limit of detection was
able to be improved to #10 copies per reaction (average
Tm=83.54uC; SD=0.33uC); however the wild type and mutant
A2058T were difficult to differentiate, as were mutants A2058G
and A2059G (Figure 2). Comparable results for both assays were
also given using the AccuMelt HRM SuperMix (Quanta
Biosciences, Gaithersburg MD USA) and/or use of the Eco
Real-Time PCR System (Illumina, San Diego USA).
HRMA screening of MG positive clinical samples
The 104 MG samples with known 23S rRNA gene sequences
(all pre- and post-treatment samples in this study) were screened
using both HRMA assays (Table 6). The 147 bp unlabelled probe
assay was able to accurately define 94/104 samples (sensitiv-
ity=0.90; 95% CI=0.83–0.95), with 61/66 (92.4%) samples
being wild type, 33/38 (86.8%) resistance types A2058G, A2059G
and A2059C. Each of the mutant controls including A2058T were
easily discriminated from the wild type samples in this screen. The
ten samples that were unable to be classified did not amplify
sufficiently to give a useable melt curve, but possessed a 100%
homology in 23S rRNA gene sequence to the primers and
unlabelled probe used (data not shown). Using the 67 bp amplicon
PCR, all 104 samples were able to be accurately defined (wild type
versus mutant), although the A2058T mutant controls also
grouped with the wild type clinical samples. Upon screening 50
MG negative clinical samples, the 147 bp unlabelled probe assay
did not give rise to any nonspecific amplification. The 67 bp assay
did give rise to amplification in 12 samples; however the melt
profiles were distinguishable with a different average Tm of
82.28uC. In addition, the aforementioned test of cure sample that
possessed both wild type and an A2058G mutation showed two
clear Tm peaks indicative of a heterozygous sample with both
assays.
Discussion
MRMM were detected in all of the azithromycin failure cases
investigated from available MG samples collected from an
Australian sexual health clinic, between December 2007 and
August 2009. We found these treatment failures were due to a
combination of both selected resistance during treatment with 1 g
azithromycin, and pre-existing transmitted resistant strains,
comprising 55% and 45% of the treatment failures, respectively.
Interestingly, there was no association with detection of pre-
existing resistance and a sexual history of an overseas source. Data
from this patient population has shown a treatment failure rate of
31% during 2007–9, an increase from the 16% treatment failure
rate previously reported from March 2005–November 2007 [15].
From these data it appears that macrolide resistance is responsible
for the azithromycin-treatment failures in this clinical population
and that both transmitted and selected resistance is contributing to
the observed reduced efficacy of azithromycin.
We have shown that detection of MRMM using rapid
molecular methodology such as HRMA is possible on pre and
post-treatment samples and that the detection of resistance is
significantly associated with treatment failure with 1 g azithromy-
cin. This technology has the capacity, in those with transmitted
resistance, to reduce the time to delivery of effective second line
agents such as moxifloxacin [15,29], rather than waiting for a test
of cure 2–4 weeks after treatment. It is also able to detect selected
resistance in individuals experiencing treatment failure and inform
clinicians that a resistant strain rather than reinfection is likely to
be responsible for treatment failure. The potential public health
benefits of this approach include reducing ongoing transmission of
resistant MG strains in the community, and by shortening time to
Table 4. 23S rRNA gene mutations present in a subset of 2007–2009 MG positive patients (n=82) with test of cure results
available post treatment with 1 g azithromycin.
Sequence type MG positive after treatment n=26 (%) MG negative after treatment n=56 (%) P value
Detection of any 23S rRNA gene
mutation
12 (44) 4 (7) ,0.0001
A2059G 7 3 0.01
A2058G 4 1 0.04
A2059C 1 - -
Wild Type 14 52 ,0.0001
doi:10.1371/journal.pone.0035593.t004
Table 5. 23S rRNA gene mutations present in a subset of 2007–2009 MG positive test of cure cases positive after treatment with
azithromycin (n=20).
Pre-treatment MG sequence type N Corresponding post-treatment MG sequence type N
Wild Type 7 A2059G 7
Wild Type 4 A2058G 4
a
A2059G 5 A2059G 5
A2058G 3 A2058G 3
A2059C 1 A2059C 1
a– one sample also carried a wild type sequence.
doi:10.1371/journal.pone.0035593.t005
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complications such as pelvic inflammatory disease.
While the detection of MRMM was shown to be highly
significantly associated with treatment failure, 7% of cases who
responded clinically to azithromycin had such mutations detected.
This is due to either spontaneous clearance or MG being present
below the detection threshold of the diagnostic assays used. The
latter explanation is supported by the frequent finding of DNA
loads close to the limit of detection in a substantial proportion of
patients [10,30]. A similar finding has been reported in a study by
Yew et al. where clearance of resistant MG was noted after an
extended course of azithromycin, although only in two patients
[23]. These patients have not represented with recurrent
symptoms at MSHC since having a negative TOC. Furthermore,
there is a possibility that patients experiencing treatment failure
were re-infected with a different MG strain harbouring the same
23S rRNA gene type, and future studies should consider
incorporating genotyping techniques to delineate this possibility
[31].
The HRMA assays described in this paper were shown to be
effective in the detection of MG 23S rRNA gene mutations
associated with macrolide resistance, and were even able to detect
a case in which mixed wild type and mutant were present. DNA
sequencing, despite being accurate in detecting these nucleotide
changes, is not practical for rapid diagnostics. HRMA is an
alternative method that is rapid and more cost effective; however,
it is recommended by manufacturers of HRMA reagents that a
minimum starting template of $1.0610
4 copies of DNA be used.
Consequently, it is not surprising then that the 147 bp amplicon
HRMA assay was not able to classify all of the sequenced samples,
as a previous study found the average concentration of MG in
clinical samples to be 3.0610
3 copies per reaction (SD=5.5610
3)
[10]. We found that HRMA is indeed capable of characterizing
low copy templates, as the use of a smaller amplicon size of 67 bp
was able to sufficiently amplify all sequenced samples. This would
ordinarily make it the ideal target for an MG HRMA assay;
however this assay was unable to detect a type 4 SNP (A2058T).
Adenine and thymine residues are accepted to be most difficult to
differentiate in DNA melt studies based on a ,0.2uC difference in
melt temperatures. Attempts were made at incorporating an
unlabelled probe to the 67 bp amplicon, but suffered sensitivity
issues (data not shown).
Both the 67 bp and 147 bp unlabelled probe HRMA assays are
capable of detecting the 23S rRNA types identified in the
literature to date relating to clinical resistance from Japan, New
Zealand and Scandinavia (A2059G, A2058G and A2058C)
[17,21,22,23]: however routine screening carried out at the
Statens Serum Institut (Denmark) has identified additional types
including those possessing type 4 SNPs (Table 1). The authors
consider that specificity outweighs sensitivity in the detection of
resistant MG infections and therefore recommend that routine
screening of MG positive clinical samples be carried out using the
147 bp unlabelled probe assay, as it will differentiate wild type
from 23S rRNA gene mutant in all cases, with the 67 bp assay to
be used in cases of low copy number templates. Continued
surveillance of the mutation types such as type 4 SNPs is
recommended to assess whether they play a significant role with
MG macrolide resistance.
The efficacy of azithromycin in published studies to date ranges
from 74–96%, with our recent data indicating an efficacy in
Melbourne at the lower end of this spectrum. Current recom-
mendations for gonorrhea state that an antibiotic is changed when
treatment failure exceeds 5% [32] and this recommendation has
also been expanded to cover chlamydia.
The key barrier to provision of highly effective therapy for MG
is that the majority of MG infections globally are treated
presumptively at the point of diagnosing the STI syndromes of
non-gonococcal urethritis and/or cervicitis, and in many settings
MG testing for diagnosis and test of cure is not available. Single
dose azithromycin has proven to be a highly acceptable and
effective for treating these STI syndromes with MG being
responsible for only 10–20% of these clinical syndromes in most
populations. Single dose (1 g) azithromycin appears to be effective
in at least 70% of cases of MG infection while the alternative
agent, doxycycline is clearly not sufficiently effective for MG.
While there are mixed data, overall extended doses of azithromy-
cin have not proven to be consistently more effective for MG than
1 g doses and are unlikely to be more effective in settings where
there is a high level of pre-existing macrolide resistance.
Our interim pragmatic recommendations for management of
NGU/cervicitis and MG infections are as follows: cases with
urethritis and cervicitis (not PID) are treated with 1 g of
azithromycin and tested where possible for MG. Where MG is
identified, a TOC is undertaken a month after treatment, and
Figure 1. Melt curves and difference plot for MG 147 bp w/unlabelled probe HRMA. i. 23S rRNA gene mutation A2058T (red). ii. Wild type
(orange). iii. 23S rRNA gene mutation A2059G (pink). iv. 23S rRNA gene mutations A2058G (blue), A2058C (green) and A2059C (yellow).
doi:10.1371/journal.pone.0035593.g001
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post-treatment samples to identify the presence and selection of
macrolide resistance. We recommend the use of moxifloxacin
400 mg daily for 7–10 in the following situations: i) persistent MG
is detected a month following treatment with 1 g of azithromycin
without a risk of reinfection, ii) macrolide resistance mutations
detected in pre- or post-treatment samples, iii) persistent symptoms
of urethritis are present following azithromycin (trichomoniasis is
not present) and there is no access to MG testing. We have
described in this paper a methodology capable of identifying those
patients with MG infection who may not respond to 1 g of
Figure 2. Melt curves and difference plot for MG 67 bp amplicon HRMA. A: 23S rRNA gene mutations A2058C (green) and A2059C (yellow).
B: 23S rRNA gene mutations A2058G (blue) and A2059G (pink). C: 23S rRNA gene mutation A2058T (red) and Wild type (orange).
doi:10.1371/journal.pone.0035593.g002
Table 6. HRMA screening of the 23S rRNA gene mutations present in a subset of 2007–2009 MG positive samples (n=154).
Sequence type 147 bp unlabelled probe assay 67 bp assay
Detection of any 23S rRNA gene mutation present in the
sample set from Melbourne
33/38 (86.8%) 38/38 (100%)
Wild Type 61/66 (92.4%) 66/66 (100%)
MG negative samples 0/50 (0%) 0/50 (0%)
a
a– 12 samples gave rise to amplification of unknown melt profile.
doi:10.1371/journal.pone.0035593.t006
Detection of Macrolide Resistance in M. genitalium
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assay.
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